A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study
that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as
adjunctive therapy in focal-onset seizures.